SCHEMBL18521567

SCHEMBL18521567

Nc1ncnc2c1ncn2[C@@H]1O[C@H](COP(=O)(O)[C@@H]2[C@H](O)[C@@H](CO)O[C@H]2n2cnc3c(=O)[nH]ncc32)[C@@H](O)[C@H]1O

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ P2RY1 P47900 7/20 0.61
▸ P2RY2 P41231 3/20 0.61
▸ SMN1; SMN2 Q16637 3/20 0.61
▸ SRC P12931 2/20 0.61
▸ TRPM2 O94759 2/20 0.61
▸ ADORA1 P30542 2/20 0.61
▸ TAS1R3 Q7RTX0 2/20 0.61
▸ TAS1R1 Q7RTX1 2/20 0.61
▸ DNPH1 O43598 1/20 0.61
▸ PRKAB2 O43741 1/20 0.61
▸ LDHA P00338 1/20 0.61
▸ ADRB2 P07550 1/20 0.61
▸ FBP1 P09467 1/20 0.61
▸ PRKAG1 P54619 1/20 0.61
▸ PRKAA2 P54646 1/20 0.61
▸ PDE4D Q08499 1/20 0.61
▸ KCNH2 Q12809 1/20 0.61
▸ PRKAA1 Q13131 1/20 0.61
▸ PDE3A Q14432 1/20 0.61
▸ P2RY11 Q96G91 1/20 0.61

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21943392 0.92 P2RY1 (0.60) P2RY1P2RY2SMN1; SMN2SRCTRPM2
SCHEMBL18510936 0.89 RNASEL (0.72) RNASEL
SCHEMBL22381499 0.88 P2RY1 (0.61) P2RY1P2RY2SMN1; SMN2SRCTRPM2
SCHEMBL22399394 0.88 P2RY1 (0.63) P2RY1P2RY2SMN1; SMN2SRCTRPM2
SCHEMBL18522032 0.88 P2RY1 (0.63) P2RY1P2RY2SMN1; SMN2SRCTRPM2
SCHEMBL18521788 0.87 P2RY1 (0.66) P2RY1P2RY2SMN1; SMN2SRCTRPM2
SCHEMBL18521402 0.85 NT5E (0.65) P2RY1P2RY2SMN1; SMN2SRCTRPM2
SCHEMBL18520792 0.85 NT5E (0.65) P2RY1P2RY2SMN1; SMN2SRCTRPM2
SCHEMBL18522039 0.85 NT5E (0.65) P2RY1P2RY2SMN1; SMN2SRCTRPM2
SCHEMBL22381606 0.85 NT5E (0.65) P2RY1P2RY2SMN1; SMN2SRCTRPM2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10766919-B2 Cyclic di-nucleotide compounds as sting agonists MERCK SHARP & DOHME CORP. (US) 2020-09-08 — — US disclosed
US-10759825-B2 Cyclic di-nucleotide compounds as STING agonists MERCK SHARP & DOHME CORP. (US) 2020-09-01 — — US disclosed
US-20170044206-A1 CYCLIC DI-NUCLEOTIDE COMPOUNDS AS STING AGONISTS MERCK SHARP & DOHME CORP. (US) 2017-02-16 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10766919-B2 Cyclic di-nucleotide compounds as sting agonists STING1, CGAS, IFNAR1 P2RY1 34/4885P2RY2 88/4885SMN1; SMN2 3075/4885
US-20170044206-A1 CYCLIC DI-NUCLEOTIDE COMPOUNDS AS STING AGONISTS STING1, CGAS, IFNAR1 P2RY1 34/4885P2RY2 88/4885SMN1; SMN2 3075/4885
US-10759825-B2 Cyclic di-nucleotide compounds as STING agonists STING1, CGAS, IFNAR1 P2RY1 34/4885P2RY2 88/4885SMN1; SMN2 3075/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback